Gaochao Lv
Overview
Explore the profile of Gaochao Lv including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang N, Zhu J, Hu X, Zhou Y, Wang Q, Cai S, et al.
Bioorg Med Chem Lett
. 2025 Mar;
:130187.
PMID: 40086606
Accurate identification of programmed cell death ligand 1 (PD-L1) expression is crucial for anti-tumor immunotherapy. However, the heterogeneity of PD-L1 expression in tumors makes it challenging to detect by immunohistochemistry....
2.
Lv G, Hu X, Zhang N, Zhu J, Gao X, Xi H, et al.
Bioorg Chem
. 2024 Sep;
153:107810.
PMID: 39276489
Although antibody-based immune checkpoint blockades have been successfully used in antitumor immunotherapy, the low response rate is currently the main problem. In this work, a small-molecule programmed cell death-ligand (PD-L1)...
3.
Chen P, Peng Y, Lv G, Xu L, Hua D, Xie M, et al.
Mol Pharm
. 2024 Jun;
21(7):3513-3524.
PMID: 38867453
The estrogen receptor α positive (ERα) subtype represents nearly 70% of all breast cancers (BCs), which seriously threaten women's health. Positron emission computed tomography (PET) characterizes its superiority in detecting...
4.
Dong Y, Wang M, Li W, Zhao K, Cui X, Yang Y, et al.
Anaesth Crit Care Pain Med
. 2024 Feb;
43(3):101358.
PMID: 38365169
Background: Most women with breast cancer are prone to postoperative sleep disturbances (POSD). Little is known about the differences between sevoflurane and propofol combined with dexmedetomidine on POSD in the...
5.
Hu X, Lv G, Hua D, Zhang N, Liu Q, Qin S, et al.
Mol Pharm
. 2023 Jul;
20(8):4228-4235.
PMID: 37409670
Nowadays, one of the most effective methods of tumor immunotherapy is blocking programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) immune checkpoints. However, there is still a...
6.
Xu L, Zhang L, Liang B, Zhu S, Lv G, Qiu L, et al.
Pharmaceuticals (Basel)
. 2023 Jun;
16(2).
PMID: 37259361
Immunotherapy blocking programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) pathway has achieved great therapeutic effect in the clinic, but the overall response rate is not satisfactory. Early studies...
7.
Chen Y, Zhu S, Fu J, Lin J, Sun Y, Lv G, et al.
J Pharm Anal
. 2023 Jan;
12(6):869-878.
PMID: 36605578
Despite advances in immunotherapy for the treatment of cancers, not all patients can benefit from programmed cell death ligand 1 (PD-L1) immune checkpoint blockade therapy. Anti-PD-L1 therapeutic effects reportedly correlate...
8.
Lin J, Gao D, Wang S, Lv G, Wang X, Lu C, et al.
J Am Chem Soc
. 2022 Dec;
145(1):748.
PMID: 36548044
No abstract available.
9.
Gao D, Miao Y, Ye S, Lu C, Lv G, Li K, et al.
RSC Adv
. 2022 Apr;
11(31):18738-18747.
PMID: 35478654
The expression level of γ-glutamyltranspeptidase (GGT) in some malignant tumors is often abnormally high, while its expression is low in normal tissues. Therefore, GGT is considered as a key biomarker...
10.
Lin J, Gao D, Wang S, Lv G, Wang X, Lu C, et al.
J Am Chem Soc
. 2022 Apr;
144(17):7667-7675.
PMID: 35452229
Target-enabled bioorthogonal reaction and self-assembly of a small-molecule probe into supramolecules have shown promise for molecular imaging. In this paper, we report a new stimuli-responsive bioorthogonal reaction scaffold () for...